Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 15,248 Shares

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 15,248 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $26.06, for a total transaction of $397,362.88. Following the transaction, the director directly owned 72,416 shares in the company, valued at approximately $1,887,160.96. The trade was a 17.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total transaction of $543,090.40.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The stock was sold at an average price of $24.20, for a total transaction of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The shares were sold at an average price of $24.11, for a total transaction of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Trading Up 2.6%

Immunome stock traded up $0.66 during mid-day trading on Monday, hitting $25.69. 1,228,372 shares of the company’s stock were exchanged, compared to its average volume of 1,385,460. Immunome, Inc. has a 1-year low of $8.66 and a 1-year high of $27.65. The stock has a 50 day moving average of $21.49 and a two-hundred day moving average of $22.16. The stock has a market cap of $2.91 billion, a P/E ratio of -10.79 and a beta of 2.07.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. As a group, research analysts predict that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in IMNM. Creative Planning boosted its stake in Immunome by 4.0% during the third quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after buying an additional 710 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of Immunome by 14.4% in the 4th quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock valued at $159,000 after buying an additional 935 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of Immunome by 1.8% during the 4th quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock worth $1,439,000 after acquiring an additional 1,167 shares during the period. Assetmark Inc. lifted its holdings in shares of Immunome by 46.6% during the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after acquiring an additional 1,442 shares during the period. Finally, Virtus Investment Advisers LLC boosted its position in shares of Immunome by 16.9% during the 4th quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock valued at $292,000 after acquiring an additional 1,970 shares in the last quarter. 44.58% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Barclays began coverage on shares of Immunome in a report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price objective for the company. Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Wedbush reiterated an “outperform” rating and issued a $31.00 target price on shares of Immunome in a report on Tuesday, July 21st. Finally, Truist Financial boosted their target price on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $34.18.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.